Shamburg News · 8-K filed Oct 23, 2026, 9:15 AM EDT
Eikon Therapeutics Presents Updated PARP1 and WRN Helicase Data at ESMO 2026
EIKN · Eikon Therapeutics, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
Eikon Therapeutics, Inc. presented initial and updated clinical data for its EIK1003 PARP1 inhibitor and initial data for EIK1004 and EIK1005 at the 2026 ESMO Congress on October 23, 2026, as described in a press release furnished as Exhibit 99.1. The filing reports objective response rates such as 14.3% (7/49) for EIK1003 monotherapy in Cohort 1A and 12.1% (7/58) for EIK1004 monotherapy. The company stated it expects further results from these programs in 2027.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-429549.
Written from the filing by Shamburg Markets. Figures are as reported by the company.